Suppr超能文献

新型Mcl-1抑制剂N-取代吲哚衍生物的发现及其构效关系研究

Discovery and structure-activity relationship studies of N-substituted indole derivatives as novel Mcl-1 inhibitors.

作者信息

Luan Shenglin, Ge Qi, Chen Yedong, Dai Mingyang, Yang Jinyu, Li Kun, Liu Dan, Zhao Linxiang

机构信息

Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.

Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.

出版信息

Bioorg Med Chem Lett. 2017 May 1;27(9):1943-1948. doi: 10.1016/j.bmcl.2017.03.028. Epub 2017 Mar 16.

Abstract

Myeloid cell leukemia-1 (Mcl-1) is an important antiapoptotic protein functioning through protein-protein interactions. We discovered LSL-A6 (2-((2-carbamoyl-1-(3-(4-methoxyphenoxy)propyl)-1H-indol-6-yl)oxy)acetic acid) with a novel N-substituted indole scaffold to interfere Mcl-1 binding as a novel Mcl-1 inhibitor. Molecular modeling indicated that this compound binds with Mcl-1 by interaction with P2 and R263 hot-spots. Structure modification focused on several moieties including indole core, hydrophobic tail and acidic chain were conducted and structure-activity relationship was analyzed. The most potent compound 24d which exhibited K value of 110nM for interfering Mcl-1 binding was obtained after hit-to-lead modification.

摘要

髓样细胞白血病-1(Mcl-1)是一种通过蛋白质-蛋白质相互作用发挥作用的重要抗凋亡蛋白。我们发现了具有新型N-取代吲哚骨架的LSL-A6(2-((2-氨基甲酰基-1-(3-(4-甲氧基苯氧基)丙基)-1H-吲哚-6-基)氧基)乙酸),作为一种新型的Mcl-1抑制剂可干扰Mcl-1的结合。分子模拟表明该化合物通过与P2和R263热点相互作用与Mcl-1结合。对包括吲哚核心、疏水尾部和酸性链在内的几个部分进行了结构修饰,并分析了构效关系。经过从苗头化合物到先导化合物的修饰后,得到了最有效的化合物24d,其干扰Mcl-1结合的K值为110nM。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验